These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19929565)

  • 1. Bilateral phrenic nerve paralysis as a manifestation of paraneoplastic syndrome.
    Otrock ZK; Barada WM; Sawaya RA; Saab JF; Bazarbachi AA
    Acta Oncol; 2010; 49(2):264-5. PubMed ID: 19929565
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.
    Amat S; Mouret-Reynier MA; Penault-Llorca F; Leheurteur M; Delva R; Coudert B; Leduc B; Dauplat J; Curé H; Chollet P
    Clin Breast Cancer; 2006 Aug; 7(3):262-9. PubMed ID: 16942644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
    Truchuelo M; Vano-Galvan S; Pérez B; Muñoz-Zato E; Jaén P
    Dermatol Online J; 2009 Mar; 15(3):7. PubMed ID: 19379651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
    Gantzer A; Regnier S; Cosnes A; Ortonne N; Wolkenstein P; Bagot M; Duong TA
    Ann Dermatol Venereol; 2011 May; 138(5):409-17. PubMed ID: 21570567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-final word on adjuvant chemotherapy for breast cancer is good news.
    Vastag B
    J Natl Cancer Inst; 2005 Aug; 97(16):1178-9. PubMed ID: 16106020
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer.
    Ferretti G; Papaldo P; Fabi A; Carlini P; Felici A; Cognetti F
    Oncologist; 2006; 11(7):853-4. PubMed ID: 16880245
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
    Shien T; Shimizu C; Seki K; Shibata T; Hojo T; Ando M; Kohno T; Katsumata N; Akashi-Tanaka S; Kinoshita T; Fujiwara Y
    Breast Cancer Res Treat; 2009 Jan; 113(2):307-13. PubMed ID: 18286370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant treatment in young women with breast cancer.
    Barnadas A
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():35-8. PubMed ID: 20711668
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
    Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
    J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.
    Köstler WJ; Steger GG; Soleiman A; Schwab B; Singer CF; Tomek S; Brodowicz T; Krainer M; Wiltschke C; Horvat R; Jakesz R; Zielinski CC
    Anticancer Res; 2004; 24(2C):1127-30. PubMed ID: 15154635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients.
    Munzone E; Nolé F; Orlando L; Mandalá M; Biffi R; Ciano C; Villa G; Civelli M; Goldhirsch A
    J Natl Cancer Inst; 2000 May; 92(9):755. PubMed ID: 10793114
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
    Huober J; von Minckwitz G; Denkert C; Tesch H; Weiss E; Zahm DM; Belau A; Khandan F; Hauschild M; Thomssen C; Högel B; Darb-Esfahani S; Mehta K; Loibl S
    Breast Cancer Res Treat; 2010 Nov; 124(1):133-40. PubMed ID: 20697801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A; Loibl S; Darb-Esfahani S; Roller M; Kronenwett R; Müller BM; Steffen J; von Toerne C; Wirtz R; Baumann I; Hoffmann G; Heinrich G; Grasshoff ST; Ulmer HU; Denkert C; von Minckwitz G
    Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of inflammatory breast cancer after neoadjuvant chemotherapy.
    Abrous-Anane S; Savignoni A; Daveau C; Pierga JY; Gautier C; Reyal F; Dendale R; Campana F; Kirova YM; Fourquet A; Bollet MA
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1055-63. PubMed ID: 20478662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
    Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
    Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.